<DOC>
	<DOCNO>NCT00678795</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Sativex® compare placebo reduce daily number episode incontinence .</brief_summary>
	<brief_title>A Parallel Group Study Compare Sativex® With Placebo Treatment Detrusor Overactivity Patients With Multiple Sclerosis</brief_title>
	<detailed_description>This ten week , multicentre , double blind , randomise , placebo control parallel group study evaluate efficacy Sativex® urge incontinence associate neurogenic unstable bladder . Multiple sclerosis patient incontinence symptom screen determine eligibility complete two-week baseline period . They return eligibility check , randomisation initial dosing . Subjects titrate self-medicate study medication study visit week two five . They also complete efficacy assessment diary-books visit .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Willing able give inform consent . Male female , age 18 year . Diagnosed MS detrusor overactivity wholly relieve current therapy . At least three incontinence episode within five consecutive day baseline period Stable dose anticholinergic medication least 14 day lead study entry . Agreement , female child bear potential male partner child bearing potential , ensure effective contraception use study three month thereafter . Has use cannabinoids ( include cannabis , Marinol® nabilone ) least seven day Visit 1 willing abstain use cannabinoids study . Agreement UK Home Office , general practitioner , consultant appropriate , notify participation study . A symptomatic UTI cause detrusor overactivity neurogenic cause due MS . Using ISC . A history schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . A history alcohol substance abuse . A severe cardiovascular disorder , ischaemic heart disease , arrhythmia ( well control atrial fibrillation ) , poorly control hypertension severe heart failure . A history epilepsy . If female , pregnant lactating , plan pregnancy occur course study . Significant renal hepatic impairment . Elective surgery procedure require general anesthesia schedule occur study . Terminal illness significant disease disorder , opinion investigator , may either put subject risk participation study influence result study , subject ability participate study . Regular levodopa ( Sinement® , Sinement Plus® , Levodopa , Ldopa , Madopar® , Benserazide ) within seven day lead study entry . Receiving unwilling stop fentanyl duration study . Known suspect hypersensitivity cannabinoids excipients study medication . Intention travel internationally donate blood study . Participation another research study 12 week lead study entry . Previous randomization study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Detrusor overactivity</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>